EC
INDP icon

EcoR1 Capital’s Indaptus Therapeutics INDP Stock Holding History

EcoR1 Capital’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-670
Closed -$13.4M – 37
2017
Q3 		$13.4M Buy
+670
New +$9.66M 1.79% 15

Other funds holding INDP

ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

EcoR1 Capital's INDP Position: Q4 2017 in Review

EcoR1 Capital sold out of Indaptus Therapeutics (INDP) in Q4 2017, closing a stake of 670 shares — an estimated $13.4M sold.

EcoR1 Capital first reported a position in INDP in Q3 2017 and held it in 1 quarter. The position peaked at $13.4M in Q3 2017. 20 funds tracked by Wall St. Rank hold INDP as of Q4 2017.

  • EcoR1 Capital reported no remaining Indaptus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • EcoR1 Capital sold 670 Indaptus Therapeutics shares in Q4 2017, an estimated $13.4M.
  • EcoR1 Capital first reported a position in Indaptus Therapeutics in Q3 2017 and held it in 1 quarter.
  • EcoR1 Capital's Indaptus Therapeutics position peaked at $13.4M in Q3 2017.
  • 20 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2017.

Based on EcoR1 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.